Alzheimer's-focused Administrative Supplements for NIH Grants that are not focused on Alzheimer's disease.

NIH 补助金的重点是阿尔茨海默病的行政补充，但不重点是阿尔茨海默病。

• 批准号: 10121141
• 负责人: Thomas J Bell
• 金额: $ 35.02万
• 依托单位: NATIONAL DISEASE RESEARCH INTERCHANGE
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-01-09 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10121141
• 关键词: Address; Administrative Supplement; Affect; Age; Alzheimer' s Disease; Alzheimer' s disease related dementia; American; Area; Award; Awareness; Biological Models; Biomedical Research; Blood; Brain; Caregivers; Clinical; Collection; Communities; Complex; Consent; Custom; Data; Dementia; Development; Diagnosis; Diagnostic; Disease; Drug Industry; Eligibility Determination; Ensure; Etiology; Exhibits; Experimental Designs; Experimental Models; Foundations; Functional disorder; Funding; Future; Generations; Grant; Healthcare Systems; Human; Human Activities; Industry; Investigation; Lead; Liquid substance; Methodology; Methods; Monitor; National Institute on Aging; Neurodegenerative Disorders; Neurologic; Organ; Parents; Participant; Pathogenesis; Patients; Performance; Play; Population; Principal Investigator; Procedures; Provider; Recommendation; Recording of previous events; Recovery; Reporting; Reproducibility; Research; Research Personnel; Research Priority; Resources; Scientific Advances and Accomplishments; Scientist; Services; Shipping; Site; Source; Standardization; Techniques; Tissue Banks; Tissues; Training; United States National Institutes of Health; Work; cohort; effective therapy; experience; experimental study; human tissue; improved; interest; invention; member; mind control; nervous system disorder; outreach; parent grant; preservation; programs; recruit; success; symposium; tissue resource; translational study; treatment strategy; trend; web site

Program Director/Principal Investigator (Last, First Middle): Bell, Thomas J. Project Summary: The development of effective treatments or cures for a wide range of diseases requires translational studies that are directly relevant to human pathophysiology. The use of human biospecimens plays a key role in accelerating scientific discoveries in neurological research by providing scientists with a direct experimental model system to advance understanding of pathogenesis and treatment of neurological disease, including Alzheimer's disease and related dementias (AD/ADRD). To address several complex issues facing AD/ADRD research, including disease etiology as well as the development of improved diagnostics and treatment strategies, investigators require access to a unique human tissue resource that could provide rigorous and uniform collection of human biospecimens from defined cohorts of both post mortem AD/ADRD donors and living AD/ADRD patients to yield consistent and reproducible experimental results for inventive and groundbreaking studies. As a leading human tissue provider for the biomedical research community, the National Disease Research Interchange (NDRI) is a 501(c)(3), not-for-profit organization that remains at the forefront of coordinating biospecimen procurement to match the needs of advancing scientific experimental methodologies, enabling cutting-edge research. For over 30 years, NDRI has received NIH funding for the parent award to this administrative supplement, the Human Tissue and Organs for Research Resource (HTORR) Grant Number: U420DO1158. To address the high priority areas of research for AD/ADRD that require both post mortem and living patient biospecimen collection that are beyond the scope of HTORR, NDRI is expanding their capabilities to create a new resource, the AD/ADRD Human Biospecimen Resource (ADBR), funded by the active award 3U42OD011158-28S3. In Program Year 2 of the ADBR, NDRI continued to lead the development of the ADBR Advisory Council to obtain ongoing recommendations regarding biospecimen collection and distribution for the ADBR that align with an unmet or under represented need in the field. For the current proposal to continue the progression of the ADBR, NDRI will: 1) identify and authorize/consent distinct cohorts of non-diseased and AD/ADRD post mortem donors 2) coordinate the recovery of AD/ADRD biospecimens, 3) distribute biospecimens and donor data to investigators or store biospecimens to support future high priority area studies, and 4) monitor the performance of the ADBR and maintain guidance for the resource from an ADBR Advisory Council. In doing so, the biospecimen collection and preservation methods will be optimized to the experimental hypotheses and procedures for each ADBR study using NDRI's experience in coordinating standardized procurement, processing, preservation and shipping methods and maintaining industry best practices and standards regarding the donation of human tissue for research. The overall objective of the ADBR is to provide approved investigators with biospecimens from defined cohorts of AD/ADRD and non-diseased control post mortem donors, to support the generation of high-quality, reproducible data for the advancement of AD/ADR research. Relevance: As the most common cause of dementia, AD is a devastating, progressive neurodegenerative disease that affects over 5.7 million Americans (Alzheimer's Association et al, 2018) and has a significant burden on the US healthcare system as well as caregivers. As of yet, there are no disease-modifying treatment options available for AD/ADRD patients, making this a high priority for the research community. The objective of this proposal is to provide biospecimens from post mortem AD/ADRD donors, as well as non- diseased control donors for the AD/ADRD Human Biospecimen Resource (ADBR) that are suitable to support critical lines of investigation that address high priority needs and key issues in the field. OMB No. 0925-0001/0002 (Rev. 01/18 Approved Through 03/31/2020) Page Continuation Format Page

计划主任/首席研究员（最后一个中间）：贝尔，托马斯·J。 项目摘要： 开发各种疾病的有效疗法或治疗方法需要翻译研究 与人类病理生理学直接相关。人类生物测量的使用在加速方面起着关键作用 神经研究中的科学发现，通过为科学家提供直接的实验模型系统 提前了解神经疾病的发病机理和治疗，包括阿尔茨海默氏病 和相关痴呆症（AD/ADRD）。解决广告/ADRD研究面临的几个复杂问题，包括 疾病病因以及改进的诊断和治疗策略的发展，研究人员 需要访问独特的人体组织资源，该资源可以提供严格而统一的人类收集 来自验尸广告/ADRD捐赠者和生活AD/ADRD患者的固定人群的生物测量，以产生 一致且可再现的实验结果，用于发明和开创性研究。作为领先的人 生物医学研究界的组织提供商，国家疾病研究互换（NDRI）是 501（c）（3），非营利组织，该组织仍然处于协调生物循环采购的最前沿 符合推进科学实验方法的需求，从而实现尖端研究。为了结束 30年，NDRI已获得该行政补充的父母奖的NIH资金，即人类 研究资源的组织和器官（HTORR）赠款编号：U420DO1158。解决高度优先级 AD/ADRD的研究领域需要验尸后和活着的患者生物传播收集 除了HTORR的范围之外，NDRI正在扩大其创建新资源的能力，广告/ADRD 由Active Award 3U42OD011158-28S3资助的人类生物传播资源（ADBR）。在计划第2年 在ADBR中，NDRI继续领导ADBR咨询委员会的发展 关于与未满足或一致的ADBR的生物测量收集和分布的建议 在该领域的代表需求。对于当前的建议，要继续ADBR的进展 意志：1）确定并授权/同意不同的非疾病和AD/ADRD验收捐赠者2） 协调AD/ADRD Biospimens的回收 或存储生物测量以支持未来的高优先级研究，4）监视ADBR的性能 并维护ADBR咨询委员会的资源指导。这样，生物循环系列 并将保存方法优化为每个ADBR的实验假设和程序 利用NDRI协调标准化采购，处理，保存和运输的经验 方法和维护行业的最佳实践和标准有关人体组织的捐赠 研究。 ADBR的总体目的是为批准的研究人员提供定义的生物测量 AD/ADRD和非疾病控制后的尸体捐赠者的同类，以支持高质量的产生， 可再现的数据，用于进步AD/ADR研究。 相关性：作为痴呆症的最常见原因，AD是毁灭性的，进行性神经退行性的 影响超过570万美国人的疾病（阿尔茨海默氏症协会等人，2018年） 美国医疗保健系统和护理人员的负担。到目前为止，尚无疾病修改 可用于广告/ADRD患者的治疗选择，这是研究界的高优先事项。这 该提案的目的是提供Mortem AD/ADRD捐赠者以及非 - 适用于支持的AD/ADRD人类生物传播资源（ADBR）的患病控制供体 批判性调查线，以解决该领域的高优先级需求和关键问题。 OMB No. 0925-0001/0002（修订版01/18通过03/31/2020批准）页面延续格式页面